Bioequivalence and bioavailability studies must meet stricter EMEA /FDA guidelines says visiongain

June 5, 2008 - PRLog -- As technology advances and regulations tighten, the competition to get new drugs on to the market has never been fiercer. The next few years look to be a critical time for the pharmaceutical industry. The development pipeline looks increasingly sparse, so equipping your business with cutting edge technologies and efficient strategies for drug development and reformulation will be the best way to keep profits high.

Visiongain’s Dissolution Testing, Bioequivalence & Bioavailability Strategies Conference is packed with the latest updates, insights and practical advice that will equip you with latest drug analysis tools. Whether your company’s strategy for development lies in the extension of product life cycle with novel reformulations, the production of generic alternatives or just increasing efficiency of existing portfolios; improving the efficacy of your dissolution testing methods and your bioavailability and bioequivalence studies will help achieve these goals.

Dissolution testing methods must keep up with the new challenges posed by poorly soluble and lipophilic drugs. Bioequivalence and bioavailability studies must meet stricter EMEA and FDA guidelines. Successful novel dosage forms and accurate PK-PD modeling must be achieved early in the development cycle. This 2-day event will provide you with an invaluable opportunity to exchange experiences through interactive discussions and hear case studies presented by the industry’s leading professionals.

Reasons to register today:
• Identify current method development problems and the associated dosage forms
• Develop useful and standardized methods to meet the challenges of new dosage forms
• Encourage innovation of new methodologies
• Gain a more in depth understanding of the IVIVC
• Explore new technologies/equipment for in vitro release testing of novel dosage forms
• Discuss of validation principles for new and standard methods

TOP QUALITY SPEAKERS INCLUDE:

- Dr Urban Fagerholm, Clinical Pharmacology, AstraZeneca
- Dr Daniel Abran, Manager, Pharmaceutical development, Sandoz
- Dr Stefaan Rossenu, PK/PD Scientist, Johnson & Johnson Research & Development
- Dr Janja Luksa, Head of Pharmacokinetic Studies, R&D, Lek Pharmaceuticals
- Dr Carlos R. Camozzi, Medical Director, Orphan Europe
- Helmut Schütz, Director, BEBAC
- Dr. Johannes Krämer, CEO, PHAST
- Dr Idris M. El-Mahdi, Associate professor of Pharmaceutics, Arab Medical Sciences University
- Dr Deirdre D'Arcy, School of Pharmacy and Pharmaceutical Sciences, Trinity College

CONFERENCE SPONSORS: SOTAX, OMICRON, COPLEY SCIENTIFIC, PHARSIGHT, PHARMATEST


Dissolution Testing, Bioequivalence and Bioavailability Strategies Conference

26th-27th June 2008,
Grosvenor Hotel, Victoria
London, UK



For a free press pass please contact sara.peerun@visiongainglobal.com

For the full agenda please click on:

http://www.biotechnology-europe.com/events/by%20country/b...